LncRNA与胃肠道肿瘤化疗耐药的研究进展

doi:10.11904/j.issn.1002-3070.2017.05.012

摘要/Abstract

摘要： 胃肠道肿瘤化疗耐药使得许多患者治疗失败,而其机制不清。随着长链非编码RNA(Long non-coding RNA,LncRNA)被发现可在转录、转录后及表观遗传学等多个方面调控机体的病理生理过程,许多研究发现LncRNA与胃肠道肿瘤耐药也密切相关。LncRNA不仅与肿瘤的十大特征有着密切联系,并且可通过影响药物转运体,以竞争内源性RNA的作用方式,影响肿瘤细胞凋亡和调节上皮间质转化等过程调控胃肠道肿瘤耐药。本文就近年来发现的与胃肠道肿瘤耐药相关的LncRNA及其参与胃肠道耐药的机制作一综述。

关键词: LncRNA, 胃肠道肿瘤, 胃癌, 结直肠癌, 耐药

Abstract: Gastrointestinal tumor chemotherapy resistance makes many patients be fail treatment,and its mechanism is unclear.The long-chain non-coding RNA(LncRNA)was found in the transcription,transcription and epigenetic,and other aspects of the regulation of the pathophysiology of the body.Many studies have found that LncRNA is also closely related to gastrointestinal cancer resistance drugs.LncRNA is not only closely related to the ten characteristics of the tumor,but it also regulates gastrointestinal cancer resistance by the impact of drug transporter,competitive endogenous RNA in the way of action,affecting tumor cell apoptosis,and regulating epithelial mesenchymal transition process.This article will review gastrointestinal cancer-related LncRNA and its participation in gastrointestinal resistance mechanism.

Key words: LncRNA, Gastrointestinal neoplasms, Gastric cancer, Colorectal cancer, Chemodrug resistance

中图分类号:

R735

孙丽娜, 赵晓迪综述, 卢瑗瑗, 王新审校. LncRNA与胃肠道肿瘤化疗耐药的研究进展[J]. 实用肿瘤学杂志, 2017, 31(5): 448-453.

SUN Lina, ZHAO Xiaodi, LU Yuanyuan, WANG Xin. Research progress of LncRNA and chemotherapy resistance in gastrointestinal neoplasms[J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(5): 448-453.

参考文献

1 Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
2 Saddoughi SA,Reinersman JM,Zhukov YO,et al.Survival after surgical resection of stage IV esophageal cancer[J].Ann Thorac Surg,2017,103(1):261-266.
3 Wohrer SS,Raderer M,Hejna M.Palliative chemotherapy for advanced gastric cancer[J].Ann Oncol,2004,15(11):1585-1595.
4 Siegel RL,Miller KD,Fedewa SA,et al.Colorectal cancer statistics,2017[J].CA Cancer J Clin,2017,67(3):177-193.
5 Holohan C,Van Schaeybroeck S,Longley DB,et al.Cancer drug resistance:an evolving paradigm[J].Nat Rev Cancer,2013,13(10):714-726.
6 Wilusz JE,Sunwoo H,Spector DL.Long noncoding RNAs:functional surprises from the RNA world[J].Genes Development,2009,23(13):1494-1504.
7 Ponting CP,Oliver PL,Reik W.Evolution and functions of long noncoding RNAs[J].Cell,2009,136(4):629-641.
8 Beermann J,Piccoli MT,Viereck J,et al.Non-coding RNAs in development and disease:Background,mechanisms,and therapeutic approaches[J].Physiol Rev,2016,96(4):1297-1325.
9 Martens JA,Laprade L,Winston F.Intergenic transcription is required to repress the Saccharomyces cerevisiae SER3 gene[J].Nature,2004,429(6991):571-574.
10 Majidinia M,Yousefi B.Long non-coding RNAs in cancer drug resistance development[J].DNA Repair(Amst),2016,45:25-33.
11 Verstraelen J,Reichl S.Multidrug resistance-associated protein(MRP1,2,4 and 5)expression in human corneal cell culture models and animal corneal tissue[J].Mol Pharm,2014,11(7):2160-2171.
12 Lan WG,Xu DH,Xu C,et al.Silencing of long non-coding RNA ANRIL inhibits the development of multidrug resistance in gastric cancer cells[J].Oncol Rep,2016,36(1):263-270.
13 Zhang XW,Bu P,Liu L,et al.Overexpression of long non-coding RNA PVT1 in gastric cancer cells promotes the development of multidrug resistance[J].Biochem Biophys Res Commun,2015,462(3):227-232.
14 Wang Y,Zhang D,Wu K,et al.Long noncoding RNA MRUL promotes ABCB1 expression in multidrug-resistant gastric cancer cell sublines[J].Mol Cell Biol,2014,34(17):3182-3193.
15 王颖.长链非编码RNA DMTF1v4(NR_024549)在胃癌多药耐药中的作用及机制研究[D].陕西:第四军医大学,2012:1-145.
16 Ma Y,Yang Y,Wang F,et al.Long non-coding RNA CCAL regulates colorectal cancer progression by activating Wnt/beta-catenin signalling pathway via suppression of activator protein 2alpha[J].Gut,2016,65(9):1494-1504.
17 Salmena L,Poliseno L,Tay Y,et al.A ceRNA hypothesis:the Rosetta stone of a hidden RNA language?[J].Cell,2011,146(3):353-358.
18 Qi X,Zhang DH,Wu N,et al.ceRNA in cancer:possible functions and clinical implications[J].J Med Genet,2015,52(10):710-718.
19 张哲.长链非编码RNA分子UCA1介导胃癌多药耐药的机制研究[D].陕西:第四军医大学,2015:1-93.
20 Fang Q,Chen X,Zhi X.Long non-coding RNA(LncRNA)urothelial carcinoma associated 1(UCA1)increases multi-drug resistance of gastric cancer via downregulating miR-27b[J].Med Sci Monit,2016,22:3506-3513.
21 Bian Z,Jin L,Zhang J,et al.LncRNA-UCA1 enhances cell proliferation and 5-fluorouracil resistance in colorectal cancer by inhibiting miR-204-5p[J].Sci Rep,2016,6:23892.
22 Liang WC,Fu WM,Wong CW,et al.The LncRNA H19 promotes epithelial to mesenchymal transition by functioning as miRNA sponges in colorectal cancer[J].Oncotarget,2015,6(26):22513-22525.
23 Yue B,Cai D,Liu C,et al.Linc00152 functions as a competing endogenous RNA to confer oxaliplatin resistance and holds prognostic values in colon cancer[J].Mol Ther,2016,24(12):2064-2077.
24 Tsuruo T,Naito M,Tomida A,et al.Molecular targeting therapy of cancer:drug resistance,apoptosis and survival signal[J].Cancer Sci,2003,94(1):15-21.
25 Shang C,Guo Y,Zhang J,et al.Silence of long noncoding RNA UCA1 inhibits malignant proliferation and chemotherapy resistance to adriamycin in gastric cancer[J].Cancer Chemother Pharmacol,2016,77(5):1061-1067.
26 Tsang WP,Wong TW,Cheung AH,et al.Induction of drug resistance and transformation in human cancer cells by the noncoding RNA CUDR[J].RNA,2007,13(6):890-898.
27 Radisky DC.Epithelial-mesenchymal transition[J].J Cell Sci,2005,118(Pt 19):4325-4326.
28 Xia H,Hui KM.MicroRNAs involved in regulating epithelial-mesenchymal transition and cancer stem cells as molecular targets for cancer therapeutics[J].Cancer Gene Ther,2012,19(11):723-730.
29 Han Y,Ye J,Wu D,et al.LEIGC long non-coding RNA acts as a tumor suppressor in gastric carcinoma by inhibiting the epithelial-to-mesenchymal transition[J].BMC Cancer,2014,14:932.
30 倪瑶瑶.下调HOTAIR表达对结直肠癌及其癌干细胞侵袭、转移和致瘤性的影响[D].南京:东南大学,2015:1-65.
31 Ding J,Li D,Gong M,et al.Expression and clinical significance of the long non-coding RNA PVT1 in human gastric cancer[J].Onco Targets Ther,2014,7:1625-1630.
32 Lee H,Kim C,Ku JL,et al.A long non-coding RNA snaR contributes to 5-fluorouracil resistance in human colon cancer cells[J].Mol Cells,2014,37(7):540-546.
33 Xiong W,Jiang YX,Ai YQ,et al.Microarray analysis of long non-coding RNA expression profile associated with 5-Fluorouracil-based chemoradiation resistance in colorectal cancer cells[J].Asian Pac J Cancer Prev,2015,16(8):3395-3402.
34 Sun QL,Zhao CP,Wang TY,et al.Expression profile analysis of long non-coding RNA associated with vincristine resistance in colon cancer cells by next-generation sequencing[J].Gene,2015,572(1):79-86.
35 Zhou XL,Wang WW,Zhu WG,et al.High expression of long non-coding RNA AFAP1-AS1 predicts chemoradioresistance and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy[J].Mol Carcinog,2016,55(12):2095-2105.
36 Jiang L,Wang W,Li G,et al.High TUG1 expression is associated with chemotherapy resistance and poor prognosis in esophageal squamous cell carcinoma[J].Cancer Chemother Pharmacol,2016,78(2):333-339.
37 Tong YS,Zhou XL,Wang XW,et al.Association of decreased expression of long non-coding RNA LOC285194 with chemoradiotherapy resistance and poor prognosis in esophageal squamous cell carcinoma[J].J Transl Med,2014,12:233.

[1]	秦文,赵楠楠,韩永焕,徐亚君. ZNF436在胃癌中的表达及调控WNT/β-catenin对胃癌细胞迁移及侵袭的影响[J]. 实用肿瘤学杂志, 2019, 33(3): 222-227.
[2]	孟海,杜观祥,朱利玲,汤琪云. WEE1在胃癌组织中的表达及对患者预后的影响[J]. 实用肿瘤学杂志, 2019, 33(3): 239-243.
[3]	刘佳音,燕飞虎,张艳桥. 凋亡基因Caspase3和Caspase7单核苷酸多态性与胃癌遗传易感性研究[J]. 实用肿瘤学杂志, 2019, 33(3): 250-255.
[4]	方琳, 刘超, 张纯慧, 张艳桥. 转移性结直肠癌维持治疗的研究现状与治疗策略[J]. 实用肿瘤学杂志, 2019, 33(2): 173-178.
[5]	佟广海, 田洋, 吴华星. 脂质组学在结直肠癌研究中的应用[J]. 实用肿瘤学杂志, 2019, 33(2): 179-192.
[6]	刘恒辰, 张新宇. Toll样受体信号通路作为结直肠癌潜在治疗靶点的研究进展[J]. 实用肿瘤学杂志, 2019, 33(2): 188-192.
[7]	白玉贤, 马仲娟, 苏颖玲, 慕安国, 谢蕊. 胃癌患者FHIT、hMLH1、p16、RAR-beta、Reprimo和TIMP3基因的甲基化研究[J]. 实用肿瘤学杂志, 2019, 33(1): 8-13.
[8]	张凤春, 江莺, 刘照南, 闫宁宁, 崔洪全, 徐迎春. 系统性炎症相关指标中性粒细胞/淋巴细胞比值及血小板/淋巴细胞比值在根治性切除术后的胃癌患者的预后意义[J]. 实用肿瘤学杂志, 2019, 33(1): 34-39.
[9]	张宝综述, 郑志超校审. 进展期胃癌淋巴结清扫研究进展[J]. 实用肿瘤学杂志, 2019, 33(1): 78-81.
[10]	唐淑丽, 何匡邦, 张纯慧, 程佳楠, 张艳桥. 胃癌组织中miR-320a和CYLD的表达及与临床病理特征及预后的关系[J]. 实用肿瘤学杂志, 2018, 32(6): 538-544.
[11]	伊庆亭, 张红军, 姜韬, 傅佳雷, 华明涛. 多烯磷脂酰胆碱在裸鼠模型中逆转胃癌细胞奥沙利铂耐药的作用及机制研究[J]. 实用肿瘤学杂志, 2018, 32(5): 385-390.
[12]	刘宏涛, 张彤彤综述, 刘雁军审校. 肥胖与结直肠癌发病机制的研究进展[J]. 实用肿瘤学杂志, 2018, 32(5): 464-467.
[13]	王志, 刘忠卫, 曾雪芸, 隋明洁, 廖静怡, 李月欢, 黄卫东, 刘国祥. 基于EQ-5D-5L的结直肠癌癌前病变患者健康相关生命质量研究[J]. 实用肿瘤学杂志, 2018, 32(4): 320-326.
[14]	崔雪阳, 邢承忠. 液体活检在结直肠癌领域的研究及应用现状[J]. 实用肿瘤学杂志, 2018, 32(4): 367-370.
[15]	李文琪, 耿敬姝. RAS/RAF突变与MSI状态在结直肠癌治疗中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(4): 371-376.